Alessandra Cesano M.D., Ph.D. — Chief Medical Officer at NanoString Technologies

Dr. Alessandra Cesano, M.D., Ph.D., has been Chief Medical Officer of NanoString Technologies, Inc. since July 06, 2015. Dr. Cesano serves as an Advisor of Neumedicines, Inc. Dr. Cesano has more than 25 years of experience in drug development, diagnostics and cancer immunology. Dr. Cesano served as Chief Medical Officer of Cleave Biosciences, Inc. from February 2014 to June 2015. She served as Chief Medical Officer of Nodality, Inc. since March 2008 and its Chief Operating Officer since November 2010. She served as Vice President and Medical Officer, Oncology Medical Research at Biogen Idec since 2006. She has over 20 years experience within the biotech / pharmaceutical industry concentrating in oncology pre-clinical research at The Wistar Institute (Philadelphia, PA), clinical development at both SmithKline Beecham Pharmaceuticals (Collegeville, PA) and Amgen Inc. She is a Member of SITC's Biomarker Task Force Working Group, which develops recommendations for the analytic and clinical validation of predictive biomarkers in immuno-oncology. Following a transition into the biopharmaceutical industry, Dr. Cesano played key roles at Amgen in the FDA approval of two cancer therapies, Vectibix and Kepivance. In addition, she holds membership in several professional and scientific societies, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematologic Association (EHA) and the Society for Immunotherapy of Cancer (SITC), and has been an author on over 100 research publications. She served as a board certified medical oncologist. She is a visiting professor and Adjunct Assistant Professor status for the University of Turin (Turin Italy) and University of Pennsylvania (Philadelphia, PA) respectively. She holds an M.D., a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin.